Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
File(s)s41408-018-0122-3.pdf (404.91 KB)
Published version
Author(s)
Type
Journal Article
Date Issued
2018-09-03
Date Acceptance
2018-06-12
Citation
Blood Cancer Journal, 2018, 8 (9)
ISSN
2044-5385
Publisher
Nature Publishing Group
Journal / Book Title
Blood Cancer Journal
Volume
8
Issue
9
Copyright Statement
© 2018 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443882700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
FOLLOW-UP
Publication Status
Published
Article Number
88
Date Publish Online
2018-09-03